HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mitochondrial myopathy associated with anti-programmed cell death 1 therapy.

AuthorsTony Ibrahim, Clovis Adam, Emilie Routier, Abdelhamid Slama, Caroline Robert
JournalEuropean journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 110 Pg. 71-73 (Mar 2019) ISSN: 1879-0852 [Electronic] England
PMID30772655 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • pembrolizumab
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal (adverse effects)
  • Antibodies, Monoclonal, Humanized (adverse effects)
  • Antineoplastic Agents, Immunological (adverse effects)
  • Female
  • Humans
  • Male
  • Melanoma (drug therapy, secondary)
  • Mitochondrial Myopathies (chemically induced, drug therapy)
  • Muscle Weakness (chemically induced)
  • Nivolumab (adverse effects)
  • Programmed Cell Death 1 Receptor (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: